This site is intended for Healthcare Professionals only.

PCCA Limited recalls batches of Ketamine oral solutions


Share post:

PCCA Limited has issued a recall for its Ketamine 50mg/5ml and 100mg/5ml oral solutions after a small number of bottles have been observed to contain crystalline material.

The company said it is recalling impacted batches from patients, pharmacies and hospitals as a precautionary measure.

“This recall is being issued as a company-led medicines recall, as this product is only supplied to a small number of customers and the company has traceability of the onward distribution by their customers to patients directly,” the MHRA said in an alert.

Affected batches: 

Ketamine 50mg in 5ml Oral Solution (unlicensed medicine)

Batch number Expiry Date Pack Size First Distributed
15806-75 07-July-2022 300ml 08-April-2022
15806-76 18-July-2022 200ml 19-April-2022
15806-77 07-August-2022 100ml 09-May-2022
15806-78 14-August-2022 200ml 16-May-2022
15806-79  4-August-2022 200ml 16-May-2022
15806-80 17-August-2022 100ml 19-May-2022

Ketamine 100mg in 5ml Oral Solution (unlicensed medicine)

Batch number Expiry Date Pack Size First Distributed
18640-20 26-June-2022 100ml 28-Mar-2022
18640-21 24-July-2022 100ml 25-April-2022
18640-22 17-August-2022 100ml 19-May-2022

Active ingredient: Ketamine Hydrochloride

Remaining stock of the above batches should be quarantined and returned to the company directly.

MHRA asked healthcare professionals who have dispensed the product to contact patients directly to return any impacted products, adding that arrangements will be considered by the company for replacement stock using alternative formulations, where appropriate.

For enquiries, contact the company via email: [email protected]


Please enter your comment!
Please enter your name here

Current Issue June 2024

Related articles

ABPI: Increased pharma exports could boost GDP by £16.3 billion

ABPI urges political leaders to enhance healthcare and economic growth through strategic partnership The Association of the British Pharmaceutical...

The Importance Of Expanding Access To Dental Care For Rural And Undeserved Populations

In many rural areas and underserved neighborhoods, a critical issue is quietly emerging. Although often overlooked, its effects...

BGMA: More than 50% of UK generics face shortages without licensed alternatives

Brexit blamed by BGMA CE, Mark Samuels, as UK faces critical shortages in generic drug supply A recent report...

Paul Burden elected BGMA Vice-Chair, bringing 25 years of industry leadership

Veteran of off-patent sector to drive strategic engagement and patient access initiatives at BGMA The British Generic Manufacturers Association...